MedTrace Logo

Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED-HED) Study

NCT02481206 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2021-01-19

Study results available
· View outcomes & findings →

Summary

A multi-center, prospective, randomized controlled clinical trial with 1:1 assignment of treatment and control. This study will evaluate the impact of wearable cardioverter defibrillator use on sudden cardiac death in incident hemodialysis patients. The study will enroll up to 2,600 subjects. A maximum of 200 sites in the USA will be used for enrollment.

Conditions

Interventions

DEVICE

Wearable Cardioverter Defibrillator

Wearable Cardioverter Defibrillator

Sponsors & Collaborators

  • Zoll Medical Corporation

    lead INDUSTRY

Principal Investigators

  • Wojciech Zareba, M.D., Ph.D · University of Rochester

  • Charles A. Herzog, M.D. · Chronic Disease Research Group, Hennepin County Medical Center, University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02481206 on ClinicalTrials.gov